The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | Exploring vaccination strategies in MPNs: the current research landscape
Morten Orebo Holmström, MD, PhD, National Center for Cancer Immune Therapy, Herlev Hospital, Copenhagen, Denmark, discusses how research efforts on vaccination strategies in myeloproliferative neoplasms (MPNs) have declined, with a growing focus on immunotherapies in recent years. Dr Holmström highlights that vaccinations have the potential to be curative; however, the large tumor burden of patients with MPNs poses a significant barrier. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
